The first pills are expected to hit the market next month and attract people who don’t want to give themselves shots.

A new FDA-approved weight-loss pill offers an alternative for patients who prefer not to use injectable medications.

This is read by an automated voice. Please report any issues or inconsistencies here. Carl Carlton, the funk and R&B singer known for upbeat, era-embodying singles like “Everlasting Love” and “She’s a ...

As both Novo Nordisk and Eli Lilly race to develop their long-anticipated oral GLP-1 obesity meds, a new report shows one taking a clear lead among potential prescribers. Spherix Global Insights ...

When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...

An Erie School District teacher faces two felony counts on allegations that he viewed child pornography on another person's phone. The teacher, Tyler G. Funk, has been placed on leave by the school ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

Nov 24 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet their main goal. Shares in Novo ...

Shares of Novo Nordisk A/S took a dive in early Monday trading after the drugmaker said oral semaglutide, which is the key ingredient in the company’s Ozempic and Wegovy diabetes and weight-loss drugs ...

Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease (AD). But perhaps the larger story associated with the unsurprising result is the market ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Elaine Chen covers biotech, co-writes The Readout newsletter, and ...